Tepezza for Thyroid Eye Disease

young woman with a beautiful smile stock image

Tepezza (teprotumumab-trbw) is a non-surgical treatment option that Dr. Ilya Leyngold offers for patients with thyroid eye disease (TED). Rather than simply targeting symptoms, it addresses the underlying disease process. For appropriate candidates, Tepezza has FDA approval for treating TED regardless of disease activity or duration. Research backs its efficacy in reducing the effects of TED, including related symptoms such as:

● Eye bulging (i.e., proptosis)
● Double vision
● Eyelid and tissue swelling
● Eye discomfort, pressure, and inflammation

Treatment recommendations are always based on each patient’s individual symptoms, medical history, and exam findings.

Tepezza: At a Glance

  • Full Name: Tepezza (teprotumumab-trbw)
  • Medication Type: Insulin-like growth factor-1 receptor (IGF-1R) inhibitor.
  • Mechanism: Blocks the IGF-1R pathway to reduce abnormal inflammatory and tissue changes occurring due to TED.
  • Administration Route: Intravenous (IV) infusion
  • Treatment Setting: In-office in a dedicated infusion room under Dr. Leyngold’s supervision
  • Typical Regimen: 8 infusions, each 3 weeks apart (about 21 weeks total)
  • Visit Duration: 90 minutes for 1st & 2nd infusion; 60 minutes for the 6 subsequent infusions

Who Do We Treat With Tepezza?

When considering Tepezza for a TED patient, Dr. Leyngold conducts a thorough evaluation. Importantly, even patients with chronic or longstanding TED may qualify, as there is no “window of treatment” for Tepezza.

Candidate Symptoms

Tepezza may prove suitable for patients with TED-related symptoms that interfere with daily life. Common candidate profiles include symptoms such as:
  • Bulging or protrusion of one or both eyes
  • Double vision
  • Swelling, redness, or puffiness around the eyes
  • Pressure or discomfort behind the eyes
  • Difficulty closing the eyes completely
  • Eye dryness or irritation
  • Noticeable symptom progression

Evaluating Candidates

Not every patient with TED will require treatment with Tepezza. As such, Dr. Leyngold assesses patient profile elements, including:
  • Severity and pattern of TED
  • How long symptoms have been present
  • Tolerance of needles and IV infusions
  • Degree of proptosis and double vision
  • Eye movement and eyelid position
  • Previous TED treatments
  • Thyroid status and overall medical history

Based on your full profile, he may recommend Tepezza for thyroid eye disease or an alternative approach. Other highly effective procedures include both noninvasive (steroid therapy) and invasive (orbital decompression, eyelid surgery) procedures.

If the path be beautiful, let us not ask where it leads.
ANATOLE FRANCE
Very Nice Experience!! With him and his whole Staff.
by Veronica G
Rated 5 out of 5
Very Nice Experience!! With him and his whole Staff. They make you feel so comfortable and assured that your in great hands I highly recommend him he’s on point with his work, also concerned when you talk to him Loved being in their care what an awesome Team!!!.

Before and After Photos

Slide the arrow to left or right to see before and after results

Our goal is to listen carefully, understand, and address your unique concerns, leaving you ecstatic about your results.

Leyngold
SCHEDULE A
CONSULTATION